Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
171.88
+0.09 (+0.05%)
4:54:26 PM EDT: $171.80 -0.08 (-0.05%)
Products, Strategic Combinations

Puretech Founded Entity Vor Biopharma Announces Collaboration With Janssen To Develop Engineered Hematopoietic Stem Cell Transplants Combined With A Bi-Specific Antibody Therapy For Acute Myeloi

Published: 07/09/2021 12:09 GMT
Johnson & Johnson (JNJ) - Puretech Founded Entity Vor Biopharma Announces Collaboration With Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-specific Antibody Therapy for Acute Myeloid Leukemia (aml).
Puretech Health - Agreement Was Facilitated by Johnson & Johnson Innovation.
Puretech Health - Vor Biopharma Will Investigate Combination of Two Technologies Into a Treatment Solution.